Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Argenx Se ADR (NQ: ARGX )

358.41 -7.79 (-2.13%)
Streaming Delayed Price Updated: 4:00 PM EDT, Apr 18, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 261,754
Open 362.34
Bid (Size) 358.41 (2)
Ask (Size) 358.94 (4)
Prev. Close 366.20
Today's Range 358.09 - 367.49
52wk Range 327.73 - 550.76
Shares Outstanding N/A
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
The Analyst Verdict: argenx In The Eyes Of 12 Experts
Via Benzinga
argenx Data Highlight Evidence that VYVGART and VYVGART Hytrulo Drive Transformative Outcomes for Patients with Debilitating Autoimmune Disease
From argenx SE
Via GlobeNewswire

Performance

YTD
-5.93%
-5.93%
1 Month
-0.87%
-0.87%
3 Month
-3.77%
-3.77%
6 Month
-26.91%
-26.91%
1 Year
-4.62%
-4.62%

More News

Read More
Cartesian Therapeutics' Rare Disease Candidate Shows Long Lasting Benefit Over Argenx's Vyvgart, Analyst Initiates With Buy
Via Benzinga
argenx Advances Clinical Development of Efgartigimod in Primary Sjogren’s Disease
From argenx SE
Via GlobeNewswire
argenx Announces Annual General Meeting of Shareholders on May 7, 2024
From argenx SE
Via GlobeNewswire
Key Takeaways From argenx Analyst Ratings
Via Benzinga
Earnings Scheduled For February 29, 2024
Via Benzinga
Tesla To $120? Here Are 10 Top Analyst Forecasts For Tuesday
Via Benzinga
argenx Announces Approval of VYVGART (efgartigimod alfa) in Japan for Adults with Primary Immune Thrombocytopenia
From argenx SE
Via GlobeNewswire
Guess? Posts Upbeat Earnings, Joins Lufax, Nortech Systems And Other Big Stocks Moving Higher On Thursday
Via Benzinga
Topics Stocks
Exposures US Equities
Why Is European Pharma Giant Argenx Valued At Over $20B Trading Higher On Thursday?
Via Benzinga
Why FactSet Research Shares Are Trading Lower By Around 5%? Here Are Other Stocks Moving In Thursday's Mid-Day Session
Via Benzinga
Argenx, Immunovant Soar — As Tourmaline Plummets — On A Rival's Lackluster Test Results
Via Investor's Business Daily
12 Health Care Stocks Moving In Thursday's Pre-Market Session
Via Benzinga
Why Micron Therapies Shares Are Trading Higher By Around 17%; Here Are 20 Stocks Moving Premarket
Via Benzinga
argenx Delivers on Promise to Transform Patient Expectations in Autoimmunity at American Academy of Neurology 2024 Annual Meeting
From argenx SE
Via GlobeNewswire
argenx Reports Full Year 2023 Financial Results and Provides Fourth Quarter Business Update
From argenx SE
Via GlobeNewswire
argenx to Present at Upcoming Investor Conferences
From argenx SE
Via GlobeNewswire
argenx to Report Full Year 2023 Financial Results and Fourth Quarter Business Update on February 29, 2024
From argenx SE
Via GlobeNewswire
3 Biotech Stocks That Could Be Multibaggers in the Making: February Edition
Via InvestorPlace
argenx Announces FDA Acceptance of Supplemental Biologics License Application with Priority Review for VYVGART Hytrulo in Chronic Inflammatory Demyelinating Polyneuropathy
From argenx SE
Via GlobeNewswire
5 medical stocks growing earnings by triple digits
Via MarketBeat
Topics Economy
Exposures Economy
New Hope For Patients With Chronic Autoimmune Conditions: Johnson & Johnson's Investigational Drug Meets Primary Goal In Two Studies
Via Benzinga
Halozyme's Ambitious Five-Year Plan: Analysts Optimistic On Growth, Eyeing Market Expansion
Via Benzinga
argenx Announces Approval of VYVDURA® (efgartigimod alfa and hyaluronidase-qvfc) Injection for Subcutaneous Use in Japan for Generalized Myasthenia Gravis
From argenx SE
Via GlobeNewswire
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.